Title:
Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View
Indication:
Breast Cancer
Location:
Texas Center for Proton Therapy
Phase: III
Title:
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
A Double-Blind, Placebo-Controlled, Randomized Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor-Positive, HER2-Negative Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer View
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: III
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View
Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
Indication:
Breast Cancer
Location:
Texas Oncology-Sherman
Phase: III
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b Abemaciclib + SOC in mBC View
Description: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer (I3Y-MC-JPBH)
Indication:
Breast Cancer
Location:
Innovative Clinical Trial Center
Phase: I
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: III
Title:
PHIII AuxLymphDisect VS AuxRad Node+Brst View
Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)
Indication:
Breast Cancer
Location:
Texas Oncology-Sherman
Phase: III
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-LIV1A Metastatic BC View
Description: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer (SGNLVA-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Mesquite
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Title:
CheckMate 848: Ph2 Nivo+Ipi Solid tumors View
Description: CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: II
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
CONTESSA:Ph3 Tesetaxel+Cape mHER2- View
Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 SYD985 HER2+ unresect adv/mBC View
Description: SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician''s choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: III
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Title:
FLEX Registry: Evaluate New Gene Express View
Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: III
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: III
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: III
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: III
Title:
Ph3 Pembro HR+/HER2- BC View
Description: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: III
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I/II
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I/II
Title:
Ph 1b2 LIV1A+Pembro 1L mTNBC View
Description: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I/II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Denton South
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: II
Title:
Ph2 SC Pertuz+Trastuz HER2+ BC View
Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
Ph2 SC Pertuz+Trastuz HER2+ BC View
Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
Ph2 SC Pertuz+Trastuz HER2+ BC View
Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
Ph2 SC Pertuz+Trastuz HER2+ BC View
Description: A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2- POSITIVE EARLY BREAST CANCER (MO40628)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
CONTESSA2: Ph2 HER2- HR+ BC View
Description: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II
Title:
CONTESSA TRIO: Tes + PD-L1 HER2- LA/MBC View
Description: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: II
Title:
CONTESSA TRIO: Tes + PD-L1 HER2- LA/MBC View
Description: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: II
Title:
CONTESSA TRIO: Tes + PD-L1 HER2- LA/MBC View
Description: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced orMetastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: II